Solid Biosciences Inc. Overview
Pro stress-test →Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, catecholaminergic polymorphic ventricular tachycardia, TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.
Strategic Profile
Pro stress-test →The company is involved in developing platform technologies, including capsid libraries, genetic regulators such as promoters, UTRs, and introns, immunomodulation technologies, manufacturing purity, and dual gene expression, a technology for packaging multiple transgenes into one capsid. Founded by those directly impacted by Duchenne, Solid's mission is to improve the daily lives of patients living with devastating rare diseases.
Competitive Landscape
Pro stress-test →Solid Biosciences competes in the rare genetic disease gene therapy space with companies like Sarepta Therapeutics, REGENXBIO, and Wave Life Sciences. The company differentiates through its proprietary platform technologies and diverse pipeline spanning both neuromuscular and cardiac indications, allowing for potential synergies and cross-program learnings.
Industry Context
Solid Biosciences Inc. operates in Biotechnology / Precision Gene Therapy.
Key facts
Founded: 2018 · Headquarters: Charlestown, Massachusetts, United States · Employees: 100 · Revenue: N/A · Market cap: $490M - $510M